Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals, Inc. (KALV)
:KALV
KALV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.00 - $0.00
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.67M
Market Cap
$0.00
Enterprise Value$0.00
Total Cash (Recent Filing)$187.65M
Total Debt (Recent Filing)$6.31M
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Sep 04, 2025EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding0
10 Day Avg. Volume1,006,536
30 Day Avg. Volume1,673,655
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$31.67Price Target Upside142.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has a strong cash balance to support the launch of Ekterly, providing financial stability for future operations.
Market ExpansionAgreements have been entered into for the commercialization of Ekterly in Japan and Canada, expanding the drug's market reach.
Regulatory ApprovalThe FDA approved Ekterly as the first and only on-demand treatment for hereditary angioedema attacks.
Bears Say
Formulary InclusionOne KOL was skeptical that Ekterly would ever be broadly added to formularies, suggesting it may only be available through medical exception pathways—a process that could place a substantial documentation burden on physician practices.
Reimbursement ChallengesThere is some noise on the burden of obtaining medical exceptions or difficulty in getting on formularies as payors might not see oral convenience.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals, Inc.’s price range in the past 12 months?
KalVista Pharmaceuticals, Inc. lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
What is KalVista Pharmaceuticals, Inc.’s market cap?
KalVista Pharmaceuticals, Inc.’s market cap is $0.00.
When is KalVista Pharmaceuticals, Inc.’s upcoming earnings report date?
KalVista Pharmaceuticals, Inc.’s upcoming earnings report date is Sep 04, 2025 which is in 28 days.
How were KalVista Pharmaceuticals, Inc.’s earnings last quarter?
KalVista Pharmaceuticals, Inc. released its earnings results on Jul 10, 2025. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.191.
Is KalVista Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts KalVista Pharmaceuticals, Inc.’s price is currently Undervalued.
Does KalVista Pharmaceuticals, Inc. pay dividends?
KalVista Pharmaceuticals, Inc. does not currently pay dividends.
What is KalVista Pharmaceuticals, Inc.’s EPS estimate?
KalVista Pharmaceuticals, Inc.’s EPS estimate is -0.96.
How many shares outstanding does KalVista Pharmaceuticals, Inc. have?
KalVista Pharmaceuticals, Inc. has 0 shares outstanding.
What happened to KalVista Pharmaceuticals, Inc.’s price movement after its last earnings report?
KalVista Pharmaceuticals, Inc. reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went down -3.002%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in KALV
KalVista Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.67 (142.68% Upside)
$31.67 (142.68% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 307.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $992.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.03%
12-Months-Change
Fundamentals
Return on Equity
-121.50%
Trailing 12-Months
Asset Growth
6.53%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Stock 12 Month Forecast
Average Price Target
$31.67
▲(142.68% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Dianthus Therapeutics
―
Replimune Group
―
LENZ Therapeutics
―
GH Research
―
Ownership Overview
11.84% Insiders
14.97% Mutual Funds
<0.01% Other Institutional Investors
62.79% Public Companies and
Individual Investors